The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice
Bone marrow-derived mesenchymal stem cells (BMSCs) have recently been introduced to treat cardiovascular diseases, such as myocardial infarction and dilated cardiomyopathy. Nevertheless, there are few researches focused on the application of BMSCs in treating viral myocarditis, not to mention its op...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2017-01-01
|
Series: | Stem Cells International |
Online Access: | http://dx.doi.org/10.1155/2017/3258035 |
id |
doaj-284f7bbe4f40484bac2fb638427bdf87 |
---|---|
record_format |
Article |
spelling |
doaj-284f7bbe4f40484bac2fb638427bdf872020-11-25T00:18:26ZengHindawi LimitedStem Cells International1687-966X1687-96782017-01-01201710.1155/2017/32580353258035The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in MiceTingting Wu0Yuan Xie1Jing Huang2Ping Li3Xuliang Wang4Yaoyao Yan5Tianhe Xia6Lei Li7Feng Zhu8Hao Li9Rongzhou Wu10Children’s Heart Center, The Second Affiliated Hospital and Yuying Children’s Hospital, Institute of Cardiovascular Development and Translational Medicine, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaChildren’s Heart Center, The Second Affiliated Hospital and Yuying Children’s Hospital, Institute of Cardiovascular Development and Translational Medicine, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaChildren’s Heart Center, The Second Affiliated Hospital and Yuying Children’s Hospital, Institute of Cardiovascular Development and Translational Medicine, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaChildren’s Heart Center, The Second Affiliated Hospital and Yuying Children’s Hospital, Institute of Cardiovascular Development and Translational Medicine, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaChildren’s Heart Center, The Second Affiliated Hospital and Yuying Children’s Hospital, Institute of Cardiovascular Development and Translational Medicine, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaChildren’s Heart Center, The Second Affiliated Hospital and Yuying Children’s Hospital, Institute of Cardiovascular Development and Translational Medicine, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaChildren’s Heart Center, The Second Affiliated Hospital and Yuying Children’s Hospital, Institute of Cardiovascular Development and Translational Medicine, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaChildren’s Heart Center, The Second Affiliated Hospital and Yuying Children’s Hospital, Institute of Cardiovascular Development and Translational Medicine, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaChildren’s Heart Center, The Second Affiliated Hospital and Yuying Children’s Hospital, Institute of Cardiovascular Development and Translational Medicine, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaChildren’s Heart Center, The Second Affiliated Hospital and Yuying Children’s Hospital, Institute of Cardiovascular Development and Translational Medicine, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaChildren’s Heart Center, The Second Affiliated Hospital and Yuying Children’s Hospital, Institute of Cardiovascular Development and Translational Medicine, Wenzhou Medical University, Wenzhou, Zhejiang 325027, ChinaBone marrow-derived mesenchymal stem cells (BMSCs) have recently been introduced to treat cardiovascular diseases, such as myocardial infarction and dilated cardiomyopathy. Nevertheless, there are few researches focused on the application of BMSCs in treating viral myocarditis, not to mention its optimal intervention timer potential mechanisms. In our study, we concentrated on finding an optimal time window to perform BMSCs treatment in a murine model of myocarditis induced by coxsackievirus B3 (CVB3). On the 1st day, 3rd day, 7th day, and 14th day after BALB/c mice were infected by CVB3, we intravenously injected equivalent BMSCs into the treatment groups. With a 28-day follow-up after inoculation, we found that the ventricular function was significantly improved in the BMSCs treatment group and cardiac fibrosis markedly ameliorated, especially when BMSCs were injected between 1 and 2 weeks after CVB3 inoculation. Furthermore, we demonstrated that after BMSCs treatment, the expressions of TGF-β, col1α1, and col3α1 were significantly decreased. Therefore, we conclude that BMSCs may have a potential to improve CVB3-induced myocarditis by ameliorating cardiac fibrosis through the inhibition of TGF-β expression.http://dx.doi.org/10.1155/2017/3258035 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tingting Wu Yuan Xie Jing Huang Ping Li Xuliang Wang Yaoyao Yan Tianhe Xia Lei Li Feng Zhu Hao Li Rongzhou Wu |
spellingShingle |
Tingting Wu Yuan Xie Jing Huang Ping Li Xuliang Wang Yaoyao Yan Tianhe Xia Lei Li Feng Zhu Hao Li Rongzhou Wu The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice Stem Cells International |
author_facet |
Tingting Wu Yuan Xie Jing Huang Ping Li Xuliang Wang Yaoyao Yan Tianhe Xia Lei Li Feng Zhu Hao Li Rongzhou Wu |
author_sort |
Tingting Wu |
title |
The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice |
title_short |
The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice |
title_full |
The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice |
title_fullStr |
The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice |
title_full_unstemmed |
The Optimal Intervention Time of Bone Marrow Mesenchymal Stem Cells in Ameliorating Cardiac Fibrosis Induced by Viral Myocarditis: A Randomized Controlled Trial in Mice |
title_sort |
optimal intervention time of bone marrow mesenchymal stem cells in ameliorating cardiac fibrosis induced by viral myocarditis: a randomized controlled trial in mice |
publisher |
Hindawi Limited |
series |
Stem Cells International |
issn |
1687-966X 1687-9678 |
publishDate |
2017-01-01 |
description |
Bone marrow-derived mesenchymal stem cells (BMSCs) have recently been introduced to treat cardiovascular diseases, such as myocardial infarction and dilated cardiomyopathy. Nevertheless, there are few researches focused on the application of BMSCs in treating viral myocarditis, not to mention its optimal intervention timer potential mechanisms. In our study, we concentrated on finding an optimal time window to perform BMSCs treatment in a murine model of myocarditis induced by coxsackievirus B3 (CVB3). On the 1st day, 3rd day, 7th day, and 14th day after BALB/c mice were infected by CVB3, we intravenously injected equivalent BMSCs into the treatment groups. With a 28-day follow-up after inoculation, we found that the ventricular function was significantly improved in the BMSCs treatment group and cardiac fibrosis markedly ameliorated, especially when BMSCs were injected between 1 and 2 weeks after CVB3 inoculation. Furthermore, we demonstrated that after BMSCs treatment, the expressions of TGF-β, col1α1, and col3α1 were significantly decreased. Therefore, we conclude that BMSCs may have a potential to improve CVB3-induced myocarditis by ameliorating cardiac fibrosis through the inhibition of TGF-β expression. |
url |
http://dx.doi.org/10.1155/2017/3258035 |
work_keys_str_mv |
AT tingtingwu theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT yuanxie theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT jinghuang theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT pingli theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT xuliangwang theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT yaoyaoyan theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT tianhexia theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT leili theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT fengzhu theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT haoli theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT rongzhouwu theoptimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT tingtingwu optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT yuanxie optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT jinghuang optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT pingli optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT xuliangwang optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT yaoyaoyan optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT tianhexia optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT leili optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT fengzhu optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT haoli optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice AT rongzhouwu optimalinterventiontimeofbonemarrowmesenchymalstemcellsinamelioratingcardiacfibrosisinducedbyviralmyocarditisarandomizedcontrolledtrialinmice |
_version_ |
1725376538557284352 |